Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding

Author(s): Veronica Ojetti*, Angela Saviano, Mattia Brigida, Luisa Saviano, Alessio Migneco and Francesco Franceschi

Volume 15, Issue 4, 2020

Page: [309 - 320] Pages: 12

DOI: 10.2174/1574887115666200624193938

Price: $65

Abstract

Background: Major bleeding is a life-threatening condition and a medical emergency with high mortality risk. It is often the complication of anticoagulant’s intake. Anticoagulants are commonly used for the prevention and treatment of thrombotic events. The standard therapy with vitamin K antagonist (warfarin) has been frequently replaced by direct oral anticoagulants (DOACs). The latter agents (rivaroxaban, apixaban, edoxaban, dabigatran, and betrixaban) showed better efficacy and safety compared to standard warfarin treatment and they are recommended for the reduction of ischemic stroke. Literature data reported a high risk of gastrointestinal bleeding with DOACs, in particular with dabigatran and rivaroxaban. In case of life-threatening gastrointestinal bleeding, these patients could benefit from the use of reversal agents.

Methods: We performed an electronic search on PUBMED of the literature concerning reversal agents for DOACs and gastrointestinal bleeding in the Emergency Department from 2004 to 2020.

Aim: This review summarizes the current evidence about three reversal agents idarucizumab, andexanet alfa and ciraparantag, and the use of the first two in the emergency setting in patients with active major bleeding or who need urgent surgery which physicians indicate for a better management approach in order to increase patient’s safety.

Conclusion: Although these agents have been marketed for five years (idarucizumab) and two years (andexanet alfa) respectively, and despite guidelines considering antidotes as first-line agents in treating life-threatening hemorrhage when available, these antidotes seem to gain access very slowly in the clinical practice. Cost, logistical aspects and need for plasma level determination of DOAC for an accurate therapeutic use probably have an impact on this phenomenon.. An expert multidisciplinary bleeding team should be established so as to implement international guidelines based on local resources and organization.

Keywords: bleeding, reversal agents, DOACs, idarucizumab, andexanet alfa, ciraparantag

« Previous Next »
Graphical Abstract

[1]
Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents. Blood 2008; 111(10): 4871-9.
[http://dx.doi.org/10.1182/blood-2007-10-120543] [PMID: 18309033]
[2]
Bracey A, Shatila W, Wilson J. Bleeding in patients receiving non-vitamin K oral anticoagulants: Clinical trial evidence. Ther Adv Cardiovasc Dis 2018; 12(12): 361-80.
[http://dx.doi.org/10.1177/1753944718801554] [PMID: 30270775]
[3]
Erika L. Hellenbart, Kathleen D Faulkenberg, Shannon W Finks. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 2017; 13: 325-42.
[http://dx.doi.org/10.2147/VHRM.S121661]
[4]
Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis 2013; 35(3): 312-9.
[http://dx.doi.org/10.1007/s11239-013-0899-7] [PMID: 23479259]
[5]
Milling TJ Jr, Frontera J. Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding. Am J Manag Care 2017; 23(4)(Suppl.): S67-80.
[PMID: 28581331]
[6]
Richard PW. Cowell. Direct oral anticoagulants: Integration into clinical practice. Postgrad Med J 2014; 0: 1-11.
[http://dx.doi.org/10.1136/postgradmedj-2013-132474]
[7]
Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: Cohort study in primary care. BMJ 2018; 362: k2505.
[http://dx.doi.org/10.1136/bmj.k2505] [PMID: 29973392]
[8]
Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23(11): 1954-63.
[http://dx.doi.org/10.3748/wjg.v23.i11.1954] [PMID: 28373761]
[9]
Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants-defining the issues and the management strategies. Thromb Haemost 2013; 110(2): 205-12.
[http://dx.doi.org/10.1160/TH13-02-0150] [PMID: 23702623]
[10]
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36(2): 386-99.
[http://dx.doi.org/10.1124/dmd.107.019083] [PMID: 18006647]
[11]
Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY. Anticoagulant-related gastrointestinal bleeding-could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med 2014; 46(8): 672-8.
[http://dx.doi.org/10.3109/07853890.2014.952327] [PMID: 25174259]
[12]
Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123(21): 2363-72.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.004747] [PMID: 21576658]
[13]
Piccini JP, Hellkamp AS, Lokhnygina Y, et al. ROCKET AF Investigators. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: Results from the ROCKET AF trial. J Am Heart Assoc 2014; 3(2)e000521
[http://dx.doi.org/10.1161/JAHA.113.000521] [PMID: 24755148]
[14]
Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[15]
Kido K, Scalese MJ. Management of oral anticoagulation therapy after gastrointestinal bleeding: Whether to, when to, and how to restart an anticoagulation therapy. Ann Pharmacother 2017; 51(11): 1000-7.
[http://dx.doi.org/10.1177/1060028017717019] [PMID: 28639882]
[16]
Miller KM, Brenner MJ. Betrixaban for extended venous thromboembolism prophylaxis in high-risk hospitalized patients: Putting the APEX results into practice. Drugs 2019; 79(3): 291-302.
[http://dx.doi.org/10.1007/s40265-019-1059-y] [PMID: 30719631]
[17]
Turpie AG, Bauer KA, Davidson BL, et al. EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101(1): 68-76.
[http://dx.doi.org/10.1160/TH08-07-0460] [PMID: 19132191]
[18]
Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: Results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013; 34(20): 1498-505.
[http://dx.doi.org/10.1093/eurheartj/eht039] [PMID: 23487517]
[19]
Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and meta-analysis. Gastroenterology 2013; 145(1): 105-112.e15.
[http://dx.doi.org/10.1053/j.gastro.2013.02.041] [PMID: 23470618]
[20]
Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61(22): 2264-73.
[http://dx.doi.org/10.1016/j.jacc.2013.03.020] [PMID: 23562920]
[21]
Garcia DA, Fisher DA, Mulder H, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2020; 221: 1-8.
[http://dx.doi.org/10.1016/j.ahj.2019.10.013] [PMID: 31896036]
[22]
Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: A population-based study. Gastroenterology 2015; 149(3): 586-95.e3.
[http://dx.doi.org/10.1053/j.gastro.2015.05.002] [PMID: 25960019]
[23]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623]
[24]
Lip GYH, Lane DA. Matching the NOAC to the Patient: Remember the modifiable bleeding risk factors. J Am Coll Cardiol 2015; 66(21): 2282-4.
[http://dx.doi.org/10.1016/j.jacc.2015.07.086] [PMID: 26610875]
[25]
Hanley JP. Warfarin reversal. J Clin Pathol 2004; 57(11): 1132-9.
[http://dx.doi.org/10.1136/jcp.2003.008904] [PMID: 15509671]
[26]
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Kardiol Pol 2018; 76(9): 1283-98.
[http://dx.doi.org/10.5603/KP.2018.0180] [PMID: 30211938]
[27]
Steffel J. Stroke prevention with non-vitamin K oral anticoagulants: For most, but not for all! Cardiology 2019; 143(3-4): 121-3.
[http://dx.doi.org/10.1159/000501586] [PMID: 31352454]
[28]
Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018; 15(5): 273-81.
[http://dx.doi.org/10.1038/nrcardio.2017.223] [PMID: 29345686]
[29]
Bauer KA. Pros and cons of new oral anticoagulants. Hematology (Am Soc Hematol Educ Program) 2013; 2013: 464-70.
[http://dx.doi.org/10.1182/asheducation-2013.1.464] [PMID: 24319220]
[30]
Minor C, Tellor KB, Armbruster AL. Edoxaban, a novel oral factor xa inhibitor. Ann Pharmacother 2015; 49(7): 843-50.
[http://dx.doi.org/10.1177/1060028015579426] [PMID: 25855704]
[31]
Lekura J, Kalus JS. Overview of betrixaban and its role in clinical practice. Am J Health Syst Pharm 2018; 75(15): 1095-102.
[http://dx.doi.org/10.2146/ajhp170785] [PMID: 29941506]
[32]
Huisman MV, Klok FA. Pharmacological properties of betrixaban. Eur Heart J Suppl 2018; 20(Suppl. E): E12-5. [E-citations].
[http://dx.doi.org/10.1093/eurheartj/suy016] [PMID: 29977164]
[33]
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf2020.
[34]
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf2020.
[35]
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf2020.
[36]
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf2020.
[37]
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf2020.
[38]
https://www.ema.europa.eu/en/documents/overview/pradaxa-epar-medicine-overview_en.pdf2020.
[39]
https://www.ema.europa.eu/en/documents/overview/xarelto-epar-medicine-overview_en.pdf2020.
[40]
https://www.ema.europa.eu/en/documents/overview/lixiana-epar-summary-public_en.pdf2020.
[41]
https://www.ema.europa.eu/en/documents/overview/eliquis-epar-summary-public_en.pdf2020.
[42]
https://www.ema.europa.eu/en/medicines/human/EPAR/dexxience2020.
[43]
Palaiodimos L, Miles J, Kokkinidis DG, et al. Reversal of novel anticoagulants in emergent surgery and trauma: A comprehensive review and proposed management algorithm. Curr Pharm Des 2018; 24(38): 4540-53.
[http://dx.doi.org/10.2174/1381612825666181226150629] [PMID: 30585542]
[44]
Kaide CG, Gulseth MP. Current strategies for the management of bleeding associated with direct oral anticoagulants and a review of investigational reversal agents. J Emerg Med 2019.
[http://dx.doi.org/10.1016/j.jemermed.2019.10.011] [PMID: 31831187]
[45]
Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the american college of cardiology task Force on expert consensus decision pathways. J Am Coll Cardiol 2017; 70(24): 3042-67.
[http://dx.doi.org/10.1016/j.jacc.2017.09.1085] [PMID: 29203195]
[46]
Gibler WB, Racadio JM, Hirsch AL, Roat TW. Management of severe bleeding in patients treated with oral anticoagulants: Proceedings monograph from the emergency medicine cardiac research and education group-international multidisciplinary severe bleeding consensus panel October 20, 2018. Crit Pathw Cardiol 2019; 18(3): 143-66.
[http://dx.doi.org/10.1097/HPC.0000000000000181] [PMID: 31348075]
[47]
Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: Functional and structural characterization. Blood 2013; 121(18): 3554-62.
[http://dx.doi.org/10.1182/blood-2012-11-468207] [PMID: 23476049]
[48]
Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017; 377(5): 431-41.
[http://dx.doi.org/10.1056/NEJMoa1707278] [PMID: 28693366]
[49]
Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373(6): 511-20.
[http://dx.doi.org/10.1056/NEJMoa1502000] [PMID: 26095746]
[50]
Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114(1): 198-205.
[PMID: 26020620]
[51]
Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19(4): 446-51.
[http://dx.doi.org/10.1038/nm.3102] [PMID: 23455714]
[52]
Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113(5): 943-51.
[http://dx.doi.org/10.1160/TH14-12-1080] [PMID: 25789661]
[53]
Kietaibl AT, Kietaibl S. New hemostatic agents: Perioperative anesthetic considerations. Curr Pharm Des 2019; 25(19): 2158-64.
[http://dx.doi.org/10.2174/1381612825666190708183127] [PMID: 31298165]
[54]
Tsai YT, Hsiao YJ, Tsai LK, et al. Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: Two cases with hemorrhagic transformation. J Neurol Sci 2018; 388: 155-7.
[http://dx.doi.org/10.1016/j.jns.2018.03.021] [PMID: 29627012]
[55]
Held V, Eisele P, Eschenfelder CC, Szabo K. Idarucizumab as antidote to intracerebral hemorrhage under treatment with dabigatran. Case Rep Neurol 2016; 8(3): 224-8.
[http://dx.doi.org/10.1159/000452096] [PMID: 27920714]
[56]
Küpper C, Feil K, Klein M, et al. Idarucizumab administration in emergency situations: The Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR). J Neurol 2019; 266(11): 2807-11.
[http://dx.doi.org/10.1007/s00415-019-09492-w] [PMID: 31375990]
[57]
Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: A randomised, placebo -controlled, double-blind phase 1 trial. Lancet 2015; 386(9994): 680-90.
[http://dx.doi.org/10.1016/S0140-6736(15)60732-2] [PMID: 26088268]
[58]
Chaudhary R, Sharma T, Garg J, et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis 2020; 49(2): 271-86.
[http://dx.doi.org/10.1007/s11239-019-01954-2] [PMID: 31512202]
[59]
Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. ANNEXA-4 iInvestigators. andexanet alfa for acute major bleeding associated with factor xa inhibitors. N Engl J Med 2016; 375(12): 1131-41.
[http://dx.doi.org/10.1056/NEJMoa1607887] [PMID: 27573206]
[60]
Connolly SJ, Crowther M, Eikelboom JW, et al. ANNEXA-4 investigators. full study report of andexanet alfa for bleeding associated with factor xa inhibitors. N Engl J Med 2019; 380(14): 1326-35.
[http://dx.doi.org/10.1056/NEJMoa1814051] [PMID: 30730782]
[61]
Kalathottukaren MT, Creagh AL, Abbina S, et al. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors. Blood Adv 2018; 2(16): 2104-14.
[http://dx.doi.org/10.1182/bloodadvances.2016003616] [PMID: 30135185]
[62]
Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa Inhibitor Activity. N Engl J Med 2015; 373(25): 2413-24.
[http://dx.doi.org/10.1056/NEJMoa1510991] [PMID: 26559317]
[63]
Siegal D, Lu G, Leeds JM, et al. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Adv 2017; 1(21): 1827-38.
[http://dx.doi.org/10.1182/bloodadvances.2017007112] [PMID: 29296829]
[64]
Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371(22): 2141-2.
[http://dx.doi.org/10.1056/NEJMc1411800] [PMID: 25371966]
[65]
Zhao S, Hong X, Cao J, Zhang J, Ma P. Current Evidence for pharmacologic reversal using direct oral anticoagulants: What’s New? Am J Cardiovasc Drugs 2019.
[PMID: 31440983]
[66]
Thalji NK, Ivanciu L, Davidson R, Gimotty PA, Krishnaswamy S, Camire RM. A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 2016; 22(8): 924-32.
[http://dx.doi.org/10.1038/nm.4149] [PMID: 27455511]
[67]
Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131(1): 82-90.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013445] [PMID: 25403645]
[68]
Majeed A, Ågren A, Holmström M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: A cohort study. Blood 2017; 130(15): 1706-12.
[http://dx.doi.org/10.1182/blood-2017-05-782060] [PMID: 28835439]
[69]
Buchheit J, Reddy P, Connors JM. Idarucizumab (Praxbind) Formulary Review. Crit Pathw Cardiol 2016; 15(3): 77-81.
[http://dx.doi.org/10.1097/HPC.0000000000000076] [PMID: 27465000]
[70]
Beik N, Reddy P, Sylvester KW, et al. Andexanet Alfa (Andexxa) formulary review. Crit Pathw Cardiol 2019; 18(2): 66-71.
[http://dx.doi.org/10.1097/HPC.0000000000000177] [PMID: 31094731]
[71]
Smith MN, Deloney L, Carter C, Weant KA, Eriksson EA. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: A retrospective study. J Thromb Thrombolysis 2019; 48(2): 250-5.
[http://dx.doi.org/10.1007/s11239-019-01846-5] [PMID: 30941571]
[72]
Frontera JA, Bhatt P, Lalchan R, et al. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis 2020; 49(1): 121-31.
[http://dx.doi.org/10.1007/s11239-019-01973-z] [PMID: 31664662]
[73]
Moia M, Squizzato A. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. Intern Emerg Med 2019; 14(8): 1233-9.
[http://dx.doi.org/10.1007/s11739-019-02177-2] [PMID: 31446606]

Rights & Permissions Print Cite
Article Metrics
36
© 2024 Bentham Science Publishers | Privacy Policy